Abstract
Disulfiram (DS), an anti-alcoholism medicine, shows strong anti-cancer activity in the laboratory, but the application in clinics for anti-cancer therapy has been limited by its prompt metabolism. Conventional liposomes have shown limited ability to protect DS. Therefore, the aim of this study is to develop PEGylated liposomes of DS for enhanced bio-stability and prolonged circulation. PEGylated liposomes were prepared using ethanol-based proliposome methods. Various ratios of phospholipids, namely: hydrogenated soya phosphatidylcholine (HSPC) or dipalmitoyl phosphatidylcholine (DPPC) and N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG2000) with cholesterol were used. DS was dissolved in the alcoholic solution in different lipid mol% ratios. The size of the resulting multilamellar liposomes was reduced by high-pressure homogenization. Liposomal formulations were characterized by size analysis, zeta potential, drug loading efficiency and stability in horse serum. Small unilamellar vesicles (SUVs; nanoliposomes) were generated with a size of approximately 80 to 120 nm with a polydispersity index (PDI) in the range of 0.1 to 0.3. Zeta potential values of all vesicles were negative, and the negative surface charge intensity tended to increase by PEGylation. PEGylated liposomes had a smaller size (80–90 nm) and a significantly lower PDI. All liposomes showed similar loading efficiencies regardless of lipid type (HSPC or DPPC) or PEGylations. PEGylated liposomes provided the highest drug biostability amongst all formulations in horse serum. PEGylated DPPC liposomes had t1/2 =77.3 ± 9.6 min compared to 9.7 ± 2.3 min for free DS. In vitro cytotoxicity on wild type and resistant colorectal cancer cell lines was evaluated by MTT assay. All liposomal formulations of DS were cytotoxic to both the wild type and resistant colorectal cancer cell lines and were able to reverse chemoresistance at low nanomolar concentrations. In conclusion, PEGylated liposomes have a greater potential to be used as an anticancer carrier for disulfiram.
Highlights
The medical need for better cancer therapies is undiminished, while drug development is slow and costly, mainly due to the large risk of toxicity of novel molecules
Cholesterol (Ch; ≥ 99%), glass vials (15 mL), fluorouracil (5FU), dimethyl sulfoxide (DMSO), thiazolyl blue tetrazolium bromide, fetal bovine serum (FBS), phosphate-buffered saline (PBS) tablets, trypan blue solution (0.4% liquid, sterile filtered), syringe filters (0.2 and 0.45 μm), syringe needles and sterile pipette tip boxes were purchased from Sigma Aldrich, Dorset, UK
Disulfiram (DS) was added in the ethanolic solution to produce a range of concentrations as mol% of the ultimate lipid phase (0, 5, 10 and 15 mol% of the lipid phase, Table 1)
Summary
The medical need for better cancer therapies is undiminished, while drug development is slow and costly, mainly due to the large risk of toxicity of novel molecules. Development of a new Pharmaceutics 2019, 11, x drug takes, on average, 15 years and costs US$1.5bn, with only 5–25% of new oncology drugs in cdleinvieclaolpdmeevneltoapcmtueanltlyacrtueaacllhyinregacthheingmtahrekemt a[r1k]e. TT[1h]i.sTdhiilsemdimlema mhaashlaesdletdo toa abboooommininggiinntteerreesstt iinn rreeppuurrppoossiinngg ooff kknnoowwnn ddrruuggss iinnttoo nneeww uussee iinn EEuurrooppee aanndd tthhee UUSSAA [[22]]. DDiissuullfifirraamm ((DDSS,, FFiigguurree 11)),, aa wweellll--kknnoowwnn aannttii--aallccoohhoolliissmm ddrruugg tthhaatt hhaass bbeeeenn uusseedd ssaaffeellyy ffoorr oovveerr 6655 yyeeaarrss,, hhaass sshhoowwnn ppootteenntt aannttiiccaanncceerr aaccttiivviittyy aaggaaiinnsstt tthhee aaggggrreessssiivvee ffoorrmm ooff ccoolloonn,, bbrreeaasstt,, lluunngg,, pprroossttaattee,, oovvaarriiaann,, cceerrvviiccaall aanndd bbrraaiinn ccaanncceerrss. TThhee aannttiiccaanncceerr aaccttiivviittyy ooff DDSS iiss ccooppppeerr ((IIII))--ddeeppeennddeenntt aass DDSS ssttrroonnggllyy cchheellaatteess CCuu ttoo ffoorrmm aa DDSS//CCuu ccoommpplleexx [[88]] ((FFiigguurree 11)). CCaanncceerr ttiissssuueess ppoosssseessss ssiiggnniiffiiccaannttllyy hhiigghheerr ccooppppeerr lleevveellss tthhaann tthheeiirr nnoorrmmaall ccoouunntteerrppaarrttss [[99]];; tthhiiss mmaayy ggrraanntt DDSS tthhee sseelleeccttiivviittyy ttoo ttaarrggeett ccaanncceerr cceellllss [[1100]]. AAlltthhoouugghh DDSS sshhoowwss ssttrroonngg aannttiiccaanncceerr aaccttiivviittyy iinn llaabboorraattoorryy,,iittssaapppplliiccaattioionnininccaanncceerrclcilniniciscsisishihgihglhylylimlimiteitdedbybyitsitbsiboi-oin-isntasbtailbitilyi.tyT.hTehheahlfa-lliff-elifoef oDfSDinS tinhethbeloboldoosdtrestarmeaims liesslsetshsatnha4nm4inm[i1n1[,1112,]1. 2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
